Soluble molecules in intravenous immunoglobulin: benefits and limitations. (1st February 2016)

• Record Type: Journal Article
• Authors: Azimi, Maryam; Aghamohammadi, Asghar; Ochs, Hans D; Rezaei, Nima
• Is Part Of: Expert review of clinical immunology. Volume 12:Number 2(2016)
• Page Start: 99
• Page End: 101
• Publication Date: 2016-02-01
• Subjects: Intravenous immunoglobulin -- efficacy -- immunomodulatory -- sCD -- sCD8 -- sHLA molecules -- sFasL; Clinical immunology -- Periodicals; 616.079
• DOI: 10.1586/1744666X.2016.1111138
• Languages: English
• ISSNs: 1744-666X

Abstract

ABSTRACT: Because of its predominance, the main immunomodulatory function of IVIg is carried out by the IgG molecules; while, based on multiple studies, the immunomodulatory role of other soluble molecules in commercial IVIg products is impossible to ignore. Although the existence of these molecules and their suppressive effects on the immune response may be considered a positive contribution to the treatment of autoimmune disorders, their presence, half-life, accumulation and immunosuppressive actions in immunocompromised patients should be monitored by physicians and manufacturing companies.